Browse investments

Invest in Rani Therapeutics Holdings Inc on Stash

Rani Therapeutics Holdings, Inc is a clinical stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. It develops the RaniPill capsule, which replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill that is designed to administer a precise therapeutic dose of medication upon deployment in the small intestine. It develops solutions to enable the oral delivery of biologics. The RaniPill capsule’s protective coating is designed to withstand the stomach acid and only dissolve in the jejunum, the upper half of the small intestine. Once dissolved, a microneedle containing a biologic drug is delivered into the vascularized wall of the small intestine so that the biologic can enter the bloodstream. Its product candidate RaniPill capsule is in a Phase I clinical trial. Its pipeline includes core product candidate programs such as RT-101, RT-105, RT-102, RT-109 and RT-110.

To buy fractional shares of Rani Therapeutics Holdings Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Ticker: RANI

Rani Therapeutics Holdings Inc

$1.50

+8.70%

(1W)

$

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

RANI Performance Breakdown

Share Price

$1.50

Today's change

-3.85%

Year to date change (YTD)

2.74%

Dividend yield

0.0

Last dividend paid

N/A

Last dividend pay date

N/A

About RANI

Rani Therapeutics Holdings, Inc is a clinical stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. It develops the RaniPill capsule, which replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill that is designed to administer a precise therapeutic dose of medication upon deployment in the small intestine. It develops solutions to enable the oral delivery of biologics. The RaniPill capsule’s protective coating is designed to withstand the stomach acid and only dissolve in the jejunum, the upper half of the small intestine. Once dissolved, a microneedle containing a biologic drug is delivered into the vascularized wall of the small intestine so that the biologic can enter the bloodstream. Its product candidate RaniPill capsule is in a Phase I clinical trial. Its pipeline includes core product candidate programs such as RT-101, RT-105, RT-102, RT-109 and RT-110.

Rani Therapeutics Holdings Inc Stock Ticker

RANI

For more information

https://www.ranitherapeutics.com/

The historical performance data for individual securities quoted on this website represents past performance reported as an average annual return for a given time horizon. Historical performance over the last 5 years, for example, is simply what the average return per year (compound annual growth rate) was for the investment over the past 5 years. Historical performance data are provided “as is” and solely for information purposes, is not advice or for trading purposes, does not reflect an investment strategy, may be subject to pricing delays, should not be used for tax reporting, may not reflect actual performance, and are gross of Stash fees. Market data provided by Thomson Reuters (Refinitiv). ©2024 Thomson Reuters. Stash cannot and does not represent or guarantee that any of the information available via Refinitiv is accurate, reliable, current, complete or appropriate for your needs. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine performance and yield are not a reliable indicator of current and future results.

Invest in Rani Therapeutics Holdings Inc on Stash

Rani Therapeutics Holdings, Inc is a clinical stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. It develops the RaniPill capsule, which replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill that is designed to administer a precise therapeutic dose of medication upon deployment in the small intestine. It develops solutions to enable the oral delivery of biologics. The RaniPill capsule’s protective coating is designed to withstand the stomach acid and only dissolve in the jejunum, the upper half of the small intestine. Once dissolved, a microneedle containing a biologic drug is delivered into the vascularized wall of the small intestine so that the biologic can enter the bloodstream. Its product candidate RaniPill capsule is in a Phase I clinical trial. Its pipeline includes core product candidate programs such as RT-101, RT-105, RT-102, RT-109 and RT-110.

To buy fractional shares of Rani Therapeutics Holdings Inc stock, you'll need to sign up for Stash and open a personal portfolio.

Disclaimer: Any investment you’ve selected here, which may be available to Stash customers on the Stash platform, is intended to be used for informational purposes only, should not be relied upon as the sole basis for making any investment decision, and is not intended to be a recommendation or advice by Stash that is based on your investment time horizon and/or risk tolerance. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. Investors who become Stash customers are offered investment advice and recommendations through various digital features such as Diversification Score Analysis based on what they tell us about their time horizon and risk tolerance. Investing Involves Risk.

Certain companies are volatile

Certain companies can be volatile, meaning the stock price fluctuates significantly. Don’t put all your eggs into one basket and remember to keep the Stash Way in mind when you invest.

Rani Therapeutics Holdings Inc stock news

CNBC

Meta's misinformation problem has local election officials struggling to get out the truth

Facebook is once again presenting problems ahead of a presidential election, but this time it's local officials sounding the alarm. Interviews with nearly a dozen regional and statewide officials with election-related duties underscore the challenges Facebook poses.

about 1 year ago

Business Insider

Mark Zuckerberg seems to have stuck the landing at Meta Connect

Mark Zuckerberg's Meta Connect keynote impressed Wall Street, boosting Meta's stock on Wednesday. Zuckerberg unveiled new Meta Quest headsets, AI features, and Orion holographic glasses.

about 1 year ago

24/7 Wall Street

Costco (COST) Price Prediction and Forecast

Headquartered in Issaquah, WA, Costco Wholesale Corporation ( NASDAQ: COST ) sells high volumes of foods and general merchandise at discounted prices through membership warehouses.

about 1 year ago

See It Market

Treasury Bonds Update: What's Next For TLT?

Instead of falling after the Fed lowered rates, the 10-year and 20+ year yields have risen. This seems incongruous given the dovish Fed talk.

about 1 year ago

Why invest with Stash?

Fractional shares

Thousands of stocks and ETFs. No investing minimums.

Unlimited trades

Plus no add-on trading commission fees.^†

Diversification analysis

Custom investment recommendations can help you diversify.

Automatic investing

Dividend reinvestment,⁸ recurring investments, and more.

The Stock-Back® Card

We’ll give you matching stock in companies you shop at.¹

Learn how to invest

Get professional advice and education at every step.

How to buy Rani Therapeutics Holdings Inc stock on Stash

Stash allows you to purchase smaller, more affordable pieces of investments (called fractional shares) rather than the whole share, which can be significantly more expensive.

Rani Therapeutics Holdings Inc’s share price is determined by its bid-ask spread, which is the difference between the price that buyers are willing to pay and the price that sellers are willing to accept. Rani Therapeutics Holdings Inc’s price can fluctuate throughout the course of each trading day—when you buy Rani Therapeutics Holdings Inc through Stash, we execute the market order during our next available trading window (we have two a day). At Stash, we don’t recommend trying to predict the market when buying investments. We believe it can be a better strategy to buy quality investments you believe in, then hang onto them.

Use our historic performance chart to see real-time Rani Therapeutics Holdings Inc stock price and the Rani Therapeutics Holdings Inc news feed to help further your research before investing in fractional shares with any dollar amount you choose.

Stash offers two subscription plans: Stash Growth and Stash+.

Each plan can help you reach different goals and offers a unique combination of financial accounts and features. All plans include access to a personal brokerage account—also known as your personal investment account. You can use your Stash personal portfolio to purchase any of the available investments on our platform, as well as access our suite of automatic saving and investing tools. Learn more about Stash pricing.

Once your market order of Rani Therapeutics Holdings Inc stock is complete, you'll officially be a shareholder of Rani Therapeutics Holdings Inc!